Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy
Crystal C. Watkins, … , Solomon H. Snyder, Christopher D. Ferris
Crystal C. Watkins, … , Solomon H. Snyder, Christopher D. Ferris
Published August 1, 2000
Citation Information: J Clin Invest. 2000;106(3):373-384. https://doi.org/10.1172/JCI8273.
View: Text | PDF | Corrigendum
Article

Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy

  • Text
  • PDF
Abstract

Gastrointestinal dysfunction is common in diabetic patients. In genetic (nonobese diabetic) and toxin-elicited (streptozotocin) models of diabetes in mice, we demonstrate defects in gastric emptying and nonadrenergic, noncholinergic relaxation of pyloric muscle, which resemble defects in mice harboring a deletion of the neuronal nitric oxide synthase gene (nNOS). The diabetic mice manifest pronounced reduction in pyloric nNOS protein and mRNA. The decline of nNOS in diabetic mice does not result from loss of myenteric neurons. nNOS expression and pyloric function are restored to normal levels by insulin treatment. Thus diabetic gastropathy in mice reflects an insulin-sensitive reversible loss of nNOS. In diabetic animals, delayed gastric emptying can be reversed with a phosphodiesterase inhibitor, sildenafil. These findings have implications for novel therapeutic approaches and may clarify the etiology of diabetic gastropathy.

Authors

Crystal C. Watkins, Akira Sawa, Samie Jaffrey, Seth Blackshaw, Roxanne K. Barrow, Solomon H. Snyder, Christopher D. Ferris

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Diabetic mice have delayed gastric emptying that is not due to hyperglyc...
Diabetic mice have delayed gastric emptying that is not due to hyperglycemia and enlarged stomachs. (a) Gastric emptying (20% dextrose) in diabetic mice. NOD-prediabetic mice (filled circles), age 10 weeks, have gastric emptying rates similar to wild-type mice (filled squares). STZ-diabetic mice (open triangles) and NOD-diabetic mice (open circles) exhibit significantly delayed gastric emptying, similar to that of nNOS–/– mice (filled triangles). Each data point represents the mean (± SEM) from groups of four to six animals. All diabetic animals exhibit some delay in gastric emptying, and this is reflected in the error bars (SEM) as shown. In some instances, the error bars are small and contained within the symbols. This experiment has been repeated twice with the same results. (b) Serum glucose levels of STZ-diabetic mice after insulin treatment. STZ-diabetic mice were either sham operated (n = 5) or treated with subcutaneous placement of an insulin-releasing implant (n = 5; see Methods). Then, serum glucose levels were determined at the indicated time points. The data shown are the means (± SEM) of five measurements for each time point. Serum glucose levels decline to around 100 mg/dL by 12 hours and remain at similar levels for 48 hours. (c) Gastric emptying in STZ-diabetic mice after 12 hours of insulin treatment. STZ-diabetic mice were either sham operated (STZd(s)) or treated with subcutaneous placement of an insulin-releasing implant (STZd(ii)) 12 hours before determination of gastric emptying. The data shown are the means (± SEM) for five to seven measurements per time point. (d) Stomachs excised from wild-type, NOD-prediabetic (NODpd), nNOS–/–, NOD-diabetic (NODd), and STZ-diabetic (STZd) mice were photographed to demonstrate the enlargement of the stomach in NOD-diabetic mice. The pictures are representative of five to eight specimens examined for each group of animals. (e) Stomachs from wild-type, NOD-prediabetic, nNOS–/–, NOD-diabetic, and STZ-diabetic mice were weighed after fasting for 4 hours. Data shown are the means (± SEM) for five specimens in each group. The stomachs from the NOD-diabetic and nNOS–/– mice weighed significantly more than those from wild-type mice. AP < 0.05 for nNOS–/– stomachs compared with wild-type and for NOD-diabetic specimens compared with NOD-prediabetic.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts